贝利尤单抗联合标准治疗系统性红斑狼疮长达十三年安全性与疗效
该多中心开放标签延续研究纳入298例活动性自身抗体阳性SLE患者,评估静脉贝利尤单抗联合标准治疗长达13年的安全性与疗效。结果显示不良事件年发生率稳定或下降,IgG水平多数维持正常,感染率稳定,SRI应答率从第1年32.8%升至第12年75.6%,基线泼尼松>7.5 mg/日者激素剂量可减少。
要点
- 贝利尤单抗联合标准治疗长达13年耐受良好,无新安全信号。
- 持续治疗者SRI应答率由第1年32.8%升至第12年75.6%。
- 基线激素>7.5 mg/日者长期治疗中激素剂量可减少。
核心结论
- 贝利尤单抗联合标准治疗在长达13年的观察中耐受良好,无新安全担忧,持续治疗者疗效得以维持。
- 对初始对贝利尤单抗应答满意的患者,长期治疗可持续良好耐受并提供长期疾病控制。
研究设计与样本
- 多中心、开放标签延续研究,纳入完成II期双盲研究的活动性自身抗体阳性SLE患者,静脉贝利尤单抗每4周一次联合标准治疗。
- 母研究476例中298例(62.6%)进入延续研究,96例(32.2%)仍在研究中;贝利尤单抗暴露中位3334.0天(范围260–4332天),总暴露2294患者年,中位输注次数115.5次(范围7–155次)。
主要发现
- 每年不良事件患者百分比保持稳定或下降,多数患者血清IgG水平维持正常,感染率保持稳定。
- SRI应答患者百分比从第1年32.8%升至第12年仍在治疗者的75.6%。
- 基线时接受>7.5 mg/日糖皮质激素的患者激素剂量减少。
关键数值与推荐
- SRI与 flare index 每16周评估一次,糖皮质激素使用每4周评估一次。
- 安全性监测自首次贝利尤单抗给药(任一研究)至末次给药后24周。
临床怎么用
- 对初始对贝利尤单抗应答满意的SLE患者,可考虑长期维持治疗以获得持续疾病控制。
- 长期治疗中应继续监测不良事件、血清IgG水平与感染情况。
- 对基线激素剂量>7.5 mg/日的患者,长期贝利尤单抗治疗有助于减少激素用量。
局限性
- 开放标签延续研究,无对照组。
- 仅32.2%的进入延续研究患者仍在研究中,存在退出偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the long-term safety and efficacy of intravenous (IV) belimumab plus standard of care (SOC) therapy for systemic lupus erythematosus (SLE) in patients with active, autoantibody-positive SLE. METHODS: The study was designed as a multicenter, open-label, continuation study of IV belimumab given every 4 weeks in conjunction with SOC therapy in patients with SLE who completed a phase II, double-blind study. Adverse events (AEs) and laboratory data were monitored from the first belimumab dose (in either study) until 24 weeks after the final dose. Efficacy assessments included SLE Responder Index (SRI) and flare index scores (each assessed at 16-week intervals) and glucocorticoid use (assessed at 4-week intervals). RESULTS: Of the 476 patients in the parent study, 298 (62.6%) entered the continuation study, of whom 96 (32.2%) remained in the study. Patients received belimumab for up to 13 years (median duration of exposure 3,334.0 days [range 260-4,332 days], total belimumab exposure 2,294 patient-years, median number of infusions 115.5 [range 7-155]). The percentage of patients with AEs each year remained stable or decreased. Normal serum IgG levels were maintained in the majority of patients over the study, and the rate of infections remained stable. The percentage of patients who achieved an SRI response increased from 32.8% (year 1) to 75.6% of those remaining on treatment at year 12. The glucocorticoid dose was decreased in patients who had been receiving >7.5 mg/day at baseline. CONCLUSION: This study is the longest to date to assess belimumab treatment in patients with SLE in clinical trials. Belimumab was well tolerated with no new safety concerns, and efficacy was maintained in patients who continued the study. For patients who initially exhibited a satisfactory response to belimumab, the treatment continues to be well tolerated and provides long-term disease control.
引用
- Wallace DJ, Ginzler EM, Merrill JT, et al. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019. PMID: 30771238. doi:10.1002/art.40861
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。